Joint statement on FDA investigation of Singulair from the ACAAI and AAAAI.
D000047:Academies and Institutes; D000085:Acetates / Q000009:adverse effects*; D003521:Cyclopropanes; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D011804:Quinolines / Q000009:adverse effects*; D013405:Suicide; D013440:Sulfides; D014481:United States; D014486:United States Food and Drug Administration
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast